264 related articles for article (PubMed ID: 22739389)
1. High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen.
Sunpath H; Wu B; Gordon M; Hampton J; Johnson B; Moosa MY; Ordonez C; Kuritzkes DR; Marconi VC
AIDS; 2012 Aug; 26(13):1679-84. PubMed ID: 22739389
[TBL] [Abstract][Full Text] [Related]
2. Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa.
Hoffmann CJ; Ledwaba J; Li JF; Johnston V; Hunt G; Fielding KL; Chaisson RE; Churchyard GJ; Grant AD; Johnson JA; Charalambous S; Morris L
Antivir Ther; 2013; 18(7):915-20. PubMed ID: 23751421
[TBL] [Abstract][Full Text] [Related]
3. High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa.
Skhosana L; Steegen K; Bronze M; Lukhwareni A; Letsoalo E; Papathanasopoulos MA; Carmona SC; Stevens WS
PLoS One; 2015; 10(2):e0118145. PubMed ID: 25659108
[TBL] [Abstract][Full Text] [Related]
4. Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
Santoro MM; Sabin C; Forbici F; Bansi L; Dunn D; Fearnhill E; Boumis E; Nicastri E; Antinori A; Palamara G; Callegaro A; Francisci D; Zoncada A; Maggiolo F; Zazzi M; Perno CF; Ceccherini-Silberstein F; Mussini C
HIV Med; 2013 Oct; 14(9):571-7. PubMed ID: 23668660
[TBL] [Abstract][Full Text] [Related]
5. The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort.
Bulteel N; Bansi-Matharu L; Churchill D; Dunn D; Bibby D; Hill T; Sabin C; Nelson M; ;
J Infect; 2014 Jan; 68(1):77-84. PubMed ID: 24055802
[TBL] [Abstract][Full Text] [Related]
6. Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy.
Etiebet MA; Shepherd J; Nowak RG; Charurat M; Chang H; Ajayi S; Elegba O; Ndembi N; Abimiku A; Carr JK; Eyzaguirre LM; Blattner WA
AIDS; 2013 Feb; 27(4):553-61. PubMed ID: 23079810
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Saekang N; Pairoj W; Chantratita W
J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
[TBL] [Abstract][Full Text] [Related]
8. Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903.
Margot NA; Lu B; Cheng A; Miller MD;
HIV Med; 2006 Oct; 7(7):442-50. PubMed ID: 16925730
[TBL] [Abstract][Full Text] [Related]
9. Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients.
Martín-Carbonero L; Gil P; García-Benayas T; Barreiro P; Blanco F; de Mendoza C; Maida I; González-Lahoz J; Soriano V
AIDS Res Hum Retroviruses; 2006 Dec; 22(12):1231-5. PubMed ID: 17209764
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.
Di Giambenedetto S; Torti C; Prosperi M; Manca N; Lapadula G; Paraninfo G; Ladisa N; Zazzi M; Trezzi M; Cicconi P; Corsi P; Nasta P; Cauda R; De Luca A; ; ;
Infection; 2009 Oct; 37(5):438-44. PubMed ID: 19669091
[TBL] [Abstract][Full Text] [Related]
11. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.
Hosseinipour MC; van Oosterhout JJ; Weigel R; Phiri S; Kamwendo D; Parkin N; Fiscus SA; Nelson JA; Eron JJ; Kumwenda J
AIDS; 2009 Jun; 23(9):1127-34. PubMed ID: 19417582
[TBL] [Abstract][Full Text] [Related]
12. Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients.
Khanlou H; Yeh V; Guyer B; Farthing C
AIDS Patient Care STDS; 2005 Mar; 19(3):135-40. PubMed ID: 15798380
[TBL] [Abstract][Full Text] [Related]
13. Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.
Rey D; Krebs M; Partisani M; Hess G; Cheneau C; Priester M; Bernard-Henry C; de Mautort E; Lang JM
J Acquir Immune Defic Syndr; 2006 Dec; 43(5):530-4. PubMed ID: 17057610
[TBL] [Abstract][Full Text] [Related]
14. K65R in subtype C HIV-1 isolates from patients failing on a first-line regimen including d4T or AZT: comparison of Sanger and UDP sequencing data.
Recordon-Pinson P; Papuchon J; Reigadas S; Deshpande A; Fleury H
PLoS One; 2012; 7(5):e36549. PubMed ID: 22615779
[TBL] [Abstract][Full Text] [Related]
15. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS;
J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763
[TBL] [Abstract][Full Text] [Related]
16. HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.
Kityo C; Thompson J; Nankya I; Hoppe A; Ndashimye E; Warambwa C; Mambule I; van Oosterhout JJ; Wools-Kaloustian K; Bertagnolio S; Easterbrook PJ; Mugyenyi P; Walker AS; Paton NI;
J Acquir Immune Defic Syndr; 2017 Jun; 75(2):e45-e54. PubMed ID: 28129253
[TBL] [Abstract][Full Text] [Related]
17. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa.
DART Virology Group and Trial Team
AIDS; 2006 Jun; 20(10):1391-9. PubMed ID: 16791013
[TBL] [Abstract][Full Text] [Related]
18. Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?
Stephan C; Dauer B; Khaykin P; Stuermer M; Gute P; Klauke S; Staszewski S
Curr HIV Res; 2009 May; 7(3):320-6. PubMed ID: 19442129
[TBL] [Abstract][Full Text] [Related]
19. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
Pozniak AL; Gallant JE; DeJesus E; Arribas JR; Gazzard B; Campo RE; Chen SS; McColl D; Enejosa J; Toole JJ; Cheng AK
J Acquir Immune Defic Syndr; 2006 Dec; 43(5):535-40. PubMed ID: 17057609
[TBL] [Abstract][Full Text] [Related]
20. K65R-associated virologic failure in HIV-infected patients receiving tenofovir-containing triple nucleoside/nucleotide reverse transcriptase inhibitor regimens.
Ruane PJ; Luber AD
MedGenMed; 2004 Apr; 6(2):31. PubMed ID: 15266257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
